Movatterモバイル変換

Triprolidin

С Википедије, слободне енциклопедије

Triprolidin
Klinički podaci

Prodajno ime	Actidil, Myidyl, Triprolidine HCL, Triprolidine Hydrochloride
Drugs.com	Monografija
Farmakokinetički podaci
Poluvreme eliminacije	4 - 6 h

Identifikatori
CAS broj	486-12-4^Y
ATC kod	R06AX07 (WHO)
PubChem	CID5282443
IUPHAR/BPS	1228
DrugBank	DB00427^Y
ChemSpider	4445597^Y
ChEMBL	CHEMBL855^Y
Hemijski podaci
Formula	C₁₉H₂₂N₂
Molarna masa	278,391
SMILES CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1
InChI InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+^Y Key:CBEQULMOCCWAQT-WOJGMQOQSA-N^Y

Fizički podaci
Tačka topljenja	60 °C (140 °F)

Triprolidin jeorgansko jedinjenje, koje sadrži 19atoma ugljenika i imamolekulsku masu od 278,391Da.^[1]^[2]^[3]^[4]^[5]^[6]

Osobine

[уреди |уреди извор]

Osobina	Vrednost
Broj akceptora vodonika	2
Broj donora vodonika	0
Broj rotacionih veza	4
Particioni koeficijent^[7] (ALogP)	4,1
Rastvorljivost^[8] (logS, log(mol/L))	-5,2
Polarna površina^[9] (PSA,Å²)	16,1

Reference

[уреди |уреди извор]

^Mann, K. V.; Crowe, J. P.; Tietze, K. J. (1989). „Nonsedating histamine H1-receptor antagonists”.Clinical Pharmacy.8 (5): 331—344.PMID 2568212.
^Simons, F. E. (1994). „H1-receptor antagonists. Comparative tolerability and safety”.Drug Safety.10 (5): 350—380.PMID 7913608.doi:10.2165/00002018-199410050-00002.
^Paton, D. M.; Webster, D. R. (1985). „Clinical pharmacokinetics of H1-receptor antagonists (The antihistamines)”.Clinical Pharmacokinetics.10 (6): 477—497.PMID 2866055.doi:10.2165/00003088-198510060-00002.
^Telekes, A.; Holland, R. L.; Withington, D. A.; Peck, A. W. (1987).„Effects of triprolidine and dipipanone in the cold induced pain test, and the central nervous system of healthy volunteers”.Br J Clin Pharmacol.24 (1): 43—50.PMC 1386278 .PMID 3620284.doi:10.1111/j.1365-2125.1987.tb03134.x.
^Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011).„DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”.Nucleic Acids Research.39 (Database issue): D1035—41.PMC 3013709 .PMID 21059682.doi:10.1093/nar/gkq1126.
^Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008).„DrugBank: A knowledgebase for drugs, drug actions and drug targets”.Nucleic Acids Research.36 (Database issue): D901—6.PMC 2238889 .PMID 18048412.doi:10.1093/nar/gkm958.
^Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”.The Journal of Physical Chemistry A.102 (21): 3762—3772.Bibcode:1998JPCA..102.3762G.doi:10.1021/jp980230o.
^Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”.Journal of Chemical Information and Computer Sciences.41 (6): 1488—1493.PMID 11749573.doi:10.1021/ci000392t.
^Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”.Journal of Medicinal Chemistry.43 (20): 3714—3717.PMID 11020286.doi:10.1021/jm000942e.